What Vascepa Costs Without Insurance
Vascepa (icosapent ethyl), used to lower triglycerides and reduce cardiovascular risk, has a list price of about $320 for a 30-day supply of 0.5g capsules or $295 for 1g versions, based on recent pharmacy data.[1] This wholesale acquisition cost doesn't include markups from pharmacies or distributors.
How Insurance Typically Lowers Out-of-Pocket Costs
Most private insurers and Medicare Part D cover Vascepa for FDA-approved uses like severe hypertriglyceridemia or CV risk reduction in statin patients. Coverage often caps patient copays at $25–$60 per month through manufacturer copay cards or assistance programs, even if the list price exceeds $4,000 annually.[2][3] Without such programs, Tier 3 formulary placement means 30–50% coinsurance, potentially $100+ monthly.
Coverage Variations by Insurer and Plan
- Commercial plans (e.g., UnitedHealthcare, Blue Cross): Prior authorization is common, requiring proof of statin intolerance or triglyceride levels >500 mg/dL. Some prefer generics or alternatives like Lovaza first.[4]
- Medicare: Covered under Part D, but with donut hole exposure where patients pay 25% of costs (around $75–$80/month at list price).[5]
- Medicaid: Varies by state; often covered with low copays but stricter prior auth.
Rejections happen if deemed non-essential or if cheaper fish oils suffice, pushing patients to list price.
Manufacturer Savings Programs and Their Insurance Rules
Amarin's Vascepa Savings Card reduces copays to $0 for eligible commercially insured patients (income limits apply post-2024 changes).[6] It can't be used with government insurance like Medicare. For uninsured, patient assistance programs offer free supply based on income <400% federal poverty level.
Why List Price Stays High Despite Insurance
Insurers negotiate net prices far below list—often 20–50% discounts via pharmacy benefit managers (PBMs) like Express Scripts.[7] List price funds these rebates but inflates costs for the uninsured or underinsured, drawing criticism for "price anchoring." Biosimilar entry could pressure this post-patent expiry.
Uninsured or High-Deductible Plan Challenges
Patients with high-deductibles (> $2,000) pay full list price until met, averaging $3,800 yearly before coverage kicks in.[8] Cash-pay discounts at pharmacies (e.g., Costco, Walmart) drop it to $250–$280/month, bypassing insurance entirely.
[1]: GoodRx - Vascepa Pricing
[2]: Amarin Vascepa Savings Program
[3]: Drugs.com - Vascepa Patient Assistance
[4]: Formulary data via OptumRx
[5]: Medicare.gov - Part D Coverage
[6]: Amarin Patient Support
[7]: DrugPatentWatch - Vascepa Pricing Insights
[8]: Kaiser Family Foundation - HDHP Analysis